European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Press release Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval July 29, 2019
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 26, 2022
ProQR Announces Results for the Second Quarter of 2015 Press release LEIDEN, the Netherlands, Aug. 19, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. August 19, 2015
ProQR Announces Results for the Fourth Quarter and Full Year 2015 Press release LEIDEN, the Netherlands, Feb. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 17, 2016